Skip to main content

Ionis Pharmaceuticals Inc

IONS
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0000874015

In the last 90 days, Ionis Pharmaceuticals Inc insiders filed 1 open-market purchase and 4 sales; 515 institutions reported holding it in 13F filings for Q2 2026, worth $14.3B in total; ARK Invest is the only superinvestor holding it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Ionis Pharmaceuticals Inc insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
1 filing
1 insider, $1.06M in total
Open-market sells
4 filings
4 insiders, $3.55M in total
Insiders trading
5
Net value
−$2.49M
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Ionis Pharmaceuticals Inc, current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Ionis Pharmaceuticals Inc
NameTitleLast reported holdingLast filingFilings, past year
Bennett C FrankEVP, Chief Scientific Officer60,128Sep 2, 20268
O'Neil Patrick R.EVP CLO & General Counsel59,205Sep 2, 202610
Monia Brett PChief Executive Officer242,760Sep 2, 202610
Birchler BrianEVP, Corp and Development Ops102,883Sep 2, 20268
Hayden Michael RDirector24,000IndirectJul 31, 20262
Reikes Peter NDirector14,222Jul 17, 20262
Hantson LudwigDirector–Jul 17, 20262
Herman Joan EDirector51,306Jul 17, 20263
Berthelsen Spencer RDirector161,233Jul 17, 20264
Diaz Allene M.Director3,811Jul 9, 20263
Kordasiewicz Holly B.EVP, Chief Development Officer22,096Jul 9, 20264
Yang Michael J.Director7,940Jul 6, 20262
Loscalzo JosephDirector36,330Jul 6, 20264
Klein Joseph IIIDirector11,014Jul 6, 20265
Baroldi JosephEVP, Chief Business Officer4,669IndirectJun 30, 20269
Schneider EugeneEVP, Chf Clinical Develop Ofcr77,114Jun 30, 20265
Swayze EricEVP Research21,759Jun 26, 20269
Parshall B LynneDirector51,344Apr 17, 20263
Jenne KyleEVP, Chf GL Pdt Str Ofcr23,713Apr 17, 20264
Devers Shannon L.EVP, Chief Human Resources Ofc16,348Apr 2, 20268
Hougen Elizabeth LEVP, Finance & CFO82,660Mar 18, 20265
Wender Joseph HDirector36,035IndirectDec 3, 20254
Geary Richard SEVP, Chief Development Officer59,657Nov 7, 20253
Cadoret-Manier OnaizaEVP,Chf GL Pdt Str & Oper Ofc35,788Sep 4, 20240
Muto Frederick TDirector59,597Jul 19, 20220

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Sep 4, 2025 (view filing)Sep 22 daysGeary Richard SEVP, Chief Development OfficerSSale−10.0K$50.37−$503.7K−11.2%79.7K after10b5-1
Sep 4, 2025 (view filing)Sep 31 dayDevers Shannon L.EVP, Chief Human Resources OfcSSale−3.16K$61.02−$192.9K−17.4%15.0K after10b5-1
Sep 4, 2025 (view filing)Sep 2-32 daysWender Joseph HDirectorSSale−28.0K$57.58−$1.61M−20.5%108.8K after3 lots10b5-1
Sep 4, 2025 (view filing)Sep 31 dayBaroldi JosephEVP, Chief Business OfficerSSale−32.8K$59.34−$1.95M−66.0%16.9K after2 lots10b5-1
Sep 4, 2025 (view filing)Sep 2-32 daysO'Neil Patrick R.EVP CLO & General CounselSSale−89.9K$60.03−$5.40M−92.5%7.33K after3 lots10b5-1
Sep 4, 2025 (view filing)Sep 2-32 daysBennett C FrankEVP, Chief Scientific OfficerSSale−38.9K$59.14−$2.30M−27.7%101.6K after2 lots10b5-1
Sep 4, 2025 (view filing)Sep 31 dayLoscalzo JosephDirectorSSale−16.0K$60.15−$962.4K−30.6%36.3K after
Sep 4, 2025 (view filing)Sep 31 daySchneider EugeneEVP, Chf Clinical Develop OfcrSSale−19.7K$60.81−$1.20M−27.6%51.5K after2 lots10b5-1
Aug 26, 2025 (view filing)Aug 224 daysDiaz Allene M.DirectorSSale−1.43K$42.53−$60.7K−7.2%18.4K after10b5-1
Aug 20, 2025 (view filing)Aug 182 daysBennett C FrankEVP, Chief Scientific OfficerSSale−10.0K$43.98−$439.8K−9.7%93.5K after10b5-1
Aug 8, 2025 (view filing)Aug 62 daysParshall B LynneDirectorSSale−5.00K$41.93−$209.7K−5.5%86.3K after2 lots10b5-1
Aug 6, 2025 (view filing)Aug 51 dayGeary Richard SEVP, Chief Development OfficerSSale−10.0K$42.86−$428.6K−10.1%89.5K after10b5-1
Aug 5, 2025 (view filing)Aug 41 daySchneider EugeneEVP, Chf Clinical Develop OfcrSSale−9.55K$42.80−$408.7K−15.6%51.5K after10b5-1
Aug 1, 2025 (view filing)Jul 302 daysMonia Brett PChief Executive OfficerSSale−2.43K$45.00−$109.4K−1.3%179.8K after10b5-1
Jul 15, 2025 (view filing)Jul 114 daysMonia Brett PChief Executive OfficerSSale−1.16K$41.74−$48.4K−0.6%179.8K after10b5-1
May 2, 2025 (view filing)May 11 dayHayden Michael RDirectorPPurchase+15.0K$31.86+$477.9K+42.6%50.2K after
Apr 17, 2025 (view filing)Apr 161 dayBirchler BrianEVP, Corp and Development OpsSSale−680$28.37−$19.3K−1.2%56.7K after
Apr 17, 2025 (view filing)Apr 161 dayJenne KyleEVP, Chf GL Pdt Str OfcrSSale−3.02K$28.36−$85.5K−21.2%11.2K after
Apr 17, 2025 (view filing)Apr 161 dayBaroldi JosephEVP, Chief Business OfficerSSale−3.93K$28.40−$111.6K−11.0%31.9K after
Mar 13, 2025 (view filing)Mar 112 daysMonia Brett PChief Executive OfficerSSale−140$32.32−$4.52K−0.1%181.0K after10b5-1
Feb 24, 2025 (view filing)Feb 204 daysO'Neil Patrick R.EVP CLO & General CounselSSale−1.21K$32.35−$39.0K−2.1%56.2K after10b5-1
Feb 6, 2025 (view filing)Feb 42 daysO'Neil Patrick R.EVP CLO & General CounselSSale−6.17K$31.62−$194.9K−9.7%57.5K after10b5-1
Feb 6, 2025 (view filing)Feb 42 daysMonia Brett PChief Executive OfficerSSale−38.8K$31.65−$1.23M−17.7%180.7K after10b5-1
Feb 3, 2025 (view filing)Jan 313 daysSwayze EricEVP ResearchSSale−1.37K$32.31−$44.2K−2.8%48.0K after
Feb 3, 2025 (view filing)Jan 313 daysSchneider EugeneEVP, Chf Clinical Develop OfcrSSale−1.48K$32.20−$47.8K−2.4%61.1K after
Feb 3, 2025 (view filing)Jan 313 daysO'Neil Patrick R.EVP CLO & General CounselSSale−1.41K$32.49−$45.7K−2.2%63.6K after
Feb 3, 2025 (view filing)Jan 313 daysMonia Brett PChief Executive OfficerSSale−13.2K$32.45−$429.7K−5.7%219.5K after
Feb 3, 2025 (view filing)Jan 313 daysHougen Elizabeth LEVP, Finance & CFOSSale−1.52K$32.44−$49.4K−1.4%110.5K after
Feb 3, 2025 (view filing)Jan 313 daysGeary Richard SEVP, Chief Development OfficerSSale−1.41K$32.40−$45.6K−1.4%99.1K after
Feb 3, 2025 (view filing)Jan 313 daysBennett C FrankEVP, Chief Scientific OfficerSSale−1.33K$32.46−$43.1K−1.4%93.1K after
Jan 17, 2025 (view filing)Jan 161 daySwayze EricEVP ResearchSSale−7.15K$32.84−$234.9K−13.5%45.7K after
Jan 17, 2025 (view filing)Jan 161 daySwayze EricEVP ResearchSSale−22$32.70−$719.4−10.7%184 after
Jan 17, 2025 (view filing)Jan 161 daySchneider EugeneEVP, Chf Clinical Develop OfcrSSale−6.52K$32.79−$213.9K−10.0%58.5K after
Jan 17, 2025 (view filing)Jan 161 dayO'Neil Patrick R.EVP CLO & General CounselSSale−7.36K$32.83−$241.6K−10.7%61.2K after
Jan 17, 2025 (view filing)Jan 161 dayMonia Brett PChief Executive OfficerSSale−33.4K$32.63−$1.09M−13.9%207.4K after
Jan 17, 2025 (view filing)Jan 161 dayHougen Elizabeth LEVP, Finance & CFOSSale−8.87K$32.81−$291.0K−7.6%107.9K after
Jan 17, 2025 (view filing)Jan 161 dayGeary Richard SEVP, Chief Development OfficerSSale−7.07K$32.86−$232.4K−6.8%96.7K after
Jan 17, 2025 (view filing)Jan 161 dayDevers Shannon L.EVP, Chief Human Resources OfcSSale−4.27K$32.78−$139.9K−21.1%15.9K after
Jan 17, 2025 (view filing)Jan 161 dayBirchler BrianEVP, Corp and Development OpsSSale−5.40K$32.70−$176.6K−8.9%55.1K after
Jan 17, 2025 (view filing)Jan 161 dayBennett C FrankEVP, Chief Scientific OfficerSSale−6.75K$32.90−$222.1K−6.9%90.9K after
Jan 17, 2025 (view filing)Jan 161 dayBaroldi JosephEVP, Chief Business OfficerSSale−3.40K$32.70−$111.2K−12.0%25.0K after
Jan 17, 2025 (view filing)Jan 161 dayBaroldi JosephEVP, Chief Business OfficerSSale−1.03K$32.70−$33.6K−25.1%3.07K after
Dec 26, 2024 (view filing)Dec 233 daysHayden Michael RDirectorPPurchase+5.00K$36.22+$181.1K+16.5%35.2K after2 lots
Nov 14, 2024 (view filing)Nov 122 daysSwayze EricEVP ResearchSSale−1.19K$37.92−$45.3K−3.4%33.7K after10b5-1
Nov 14, 2024 (view filing)Nov 122 daysMonia Brett PChief Executive OfficerSSale−6.63K$38.05−$252.3K−3.8%167.4K after10b5-1
Nov 14, 2024 (view filing)Nov 122 daysLoscalzo JosephDirectorSSale−13.5K$37.86−$511.4K−29.5%32.3K after10b5-1
Oct 17, 2024 (view filing)Oct 161 daySwayze EricEVP ResearchSSale−53$38.31−$2.03K−25.2%157 after
Sep 4, 2024 (view filing)Feb 2215 daysGeary Richard SEVP, Chief Development OfficerSSale−2.00K$50.04−$99.8K−2.2%87.3K afterAmended
Sep 4, 2024 (view filing)Feb 2215 daysHougen Elizabeth LEVP, Finance & CFOSSale−2.16K$49.54−$107.1K−2.3%92.9K afterAmended
Sep 4, 2024 (view filing)Feb 2215 daysO'Neil Patrick R.EVP CLO & General CounselSSale−2.00K$49.67−$99.1K−3.9%48.6K afterAmended